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Different mechanisms underlying acquired resistance (AR) to epidermal growth factor receptor (EGFR) inhibi-
tors in EGFR-mutated lung cancer are known, among them 
the EGFRT790M mutation in approximately 50% and MET-
amplifications in approximately 5% of these patients.1 Here, 
we describe a patient with AR harboring both genetic aberra-
tions at distinct tumor sites resulting in mixed response pat-
terns following biopsy-guided sequential targeted therapy.
CASE REPORT
A 55-year-old male Caucasian patient was diagnosed with 
lung adenocarcinoma Union for International Cancer Control 
stage IV (cT4cN1cM1b PUL/PLEU/OSS) in October 2011. 
EGFRL858R mutation was diagnosed by dideoxy sequencing. 
After several lines of treatment including erlotinib, cisplatin/
pemetrexed, and afatinib/cetuximab, he presented in July 2013 
with disease progression. Next-generation sequencing based 
analysis of the rebiopsy of the primary tumor (left lung upper 
lobe) revealed EGFRL858R and two different TP53 mutations 
(R110C and C277* [allele frequencies 4% vs. 26%, suggest-
ing biclonality]), but no aberration associated with AR (Table 1; 
Sanger sequencing was used for validation and showed no 
discrepancies). Treatment was initiated with docetaxel/gem-
citabine, and massive progression was diagnosed in September 
2013 (lung, liver, myocard, and soft-tissue left arm; Fig. 1A). 
Rebiopsy of the lesion in the left arm detected EGFRL858R, 
TP53C277*, and high-level MET-amplification (MET/centromer7 
ratio, 8.3; cutoff for high-level amplification, 2.0)2 in the absence 
of EGFRT790M. Treatment with crizotinib (2 × 250 mg/d) in com-
bination with erlotinib (100 mg/d) was started. After 1 week of 
therapy, fluorodeoxyglucose (18F)-positron emission tomog-
raphy–computed tomography showed a dramatic metabolic 
response (Fig. 1B) in the arm, the liver, and the myocardium, 
with improvement of the patient’s performance state. However, 
the primary tumor (left lung) did not respond (Fig. 1B). In 
December 2013, the patient presented with increasing dyspnea 
(Fig. 1C). Although complete metabolic response was main-
tained in liver and soft-tissue metastases, metabolic progression 
occurred in myocardial metastasis. Combination therapy was 
maintained. In January 2014, the patient presented with dyspnea 
and left pleural effusion. Analysis of pleural effusion (Fig. 1D) 
revealed EGFRL858R, TP53R110C, low-level MET-amplification, 
and EGFRT790M. The same mutations were detected in periph-
eral blood. Crizotinib was stopped, and the patient was enrolled 
into a trial evaluating a third generation EGFR-tyrosine kinase 
inhibitor (TKI) (NCT01802632) in February 2014. After 2 
weeks, fluorodeoxyglucose (18F)-positron emission tomogra-
phy–computed tomography showed control of the primary lung 
tumor but a strong increase in activity in the liver and myo-
cardium (Fig. 1E). The patient was withdrawn from the trial 
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TABLE 1.  Biopsies Performed and Molecular Findings
Date Localization Method Results
October 2011 Lung (primarius) Sanger EGFR L858R
June 2013 Lung (primarius) NGS/FISH/Sanger EGFR L858R, TP53 C277*, TP53 R110C, and no METamp
October 2013 Muscle right arm NGS/FISH/Sanger EGFR L858R, TP53 C277*, and high-level METamp
January 2014 Pleural effusion NGS/FISH/Sanger EGFR L858R, TP53 R110C, low-level METamp, and EGFR T790M
January 2014 Peripheral blood CAGEa EGFR L858R, EGFR T790M, and TP53 R110C
April 2014 Pleural effusion NGS/FISH EGFR L858R, EGFR T790M, TP53 R110C, and no METamp
a An NGS-based target enrichment assay detecting rearrangements, amplifications, deletions, and point mutations, in more than 300 cancer relevant genes.
NGS, next-generation sequencing; FISH, fluorescence in situ hybridization; Sanger, dideoxy sequencing; CAGE, Cancer genome scanner® (Blackfield AG, Cologne, Germany).
FIGURE 1.  Fluorodeoxyglucose (18F)-positron emission tomography–computed tomography results. A, October 2013: mas-
sive progression after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor resistance and chemotherapy (lung, 
myocardial infiltration, liver, and soft-tissue left arm). Rebiopsy left arm: EGFRL858R, high-level METamp, TP53C277*, and TP53R110C. 
B, November 2013: complete metabolic response of myocard-tissue, liver-tissue, and soft-tissue metastases after 8 days of crizo-
tinib and erlotinib. C, December 2013: ongoing metabolic response of myocard-tissue, liver-tissue, and soft-tissue metastases 
under crizotinib and erlotinib. D, January 2014: ongoing metabolic response of liver-tissue and soft-tissue metastases. Metabolic 
progression of myocard infiltrating tumor and progressive pleural effusion left. Molecular analysis of pleural effusion: EGFRL858R, 
EGFRT790M, TP53R110C, and low-level METamp. Peripheral blood: EGFRL858R, EGFRT790M, and TP53R110C (MET status not assessable). 
Stop of crizotinib and erlotinib treatment, start of AZD9291. E, March 2014: stable metabolic disease in lung tumor, tumor 
progression in myocard- and liver metastases, tumor control of the soft-tissue metastasis in the arm. Stop of AZD9291, restart 
with crizotinib. F, April 2014: complete metabolic response of liver- and myocardial metastases, ongoing tumor control of the 
soft-tissue metastasis. Progress of pleural effusion. Patient died after 3 weeks of crizotinib treatment. Molecular analysis of pleu-
ral effusion: EGFRL858R, EGFRT790M, TP53R110C, and no METamp.
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as no concomitant antineoplastic treatment was allowed, and 
crizotinib treatment was restarted. Three weeks later, again a 
nearly complete metabolic response of the metastases presum-
ably driven by high-level MET-amplification was observed 
(Fig. 1F). However, the patient suffered from recurrent pleural 
effusions and his performance state worsened. He finally died 
in April 2014.
DISCUSSION
This report describes a patient with acquired EGFR-tyrosine 
kinase inhibitor resistance harboring two different resis-
tance mechanisms, namely EGFRT790M and high-level MET-
amplification, at different tumor sites. Despite rebiopsy-guided 
effective temporary control of the tumor clone harboring 
high-level MET amplification with a potent MET-inhibitor3 
tumor activity could not be persistently controlled because of 
clonal heterogeneity and finally led to fatal progression of the 
disease (Figs. 2 and 3). These observations not only provide a 
rationale for early combination therapy in AR but also point to 
the limitations of our current paradigmatic understanding of 
driver-mutation directed therapy and underlines recent anal-
yses demonstrating genetic variability in patients with lung 
cancer.4,5
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FIGURE 2.  Overview of the findings in the resistance setting after erlotinib treatment (November 2011–July 2012) and afa-
tinib/cetuximab treatment (November 2012–June 2013) with intercurrent radiation/chemotherapy.
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FIGURE 3: Liquid biopsy reveals epidermal growth factor receptor (EGFR) and TP53 mutations: results of the peripheral blood 
analysis (January 2014). A, EGFRL858R mutation with an allele frequency of 13%. B, EGFRT790M mutation with an allele frequency of 
10%. C, TP53R110C mutation with an allele frequency of 9%. All identified and illustrated by integrative genome viewer.
